HR 5552, the "Eliminate Shutdowns Act," would automatically continue federal funding for most government programs during a funding gap. If Congress fails to pass annual appropriations bills by the start of a fiscal year, the bill would automatically provide funding at the previous year's level for 14 days, extending in 14-day increments until a new funding bill is enacted. This applies to all federal programs except those specifically prohibited or covered by other laws, including maintaining current funding for entitlement programs like food assistance under the Food and Nutrition Act. The bill aims to prevent shutdowns by ensuring continuous operations without requiring new congressional action during the funding gap. It would take effect on September 30, 2025.
This bill extends the expiration date for exemptions allowing certain vehicles to use High Occupancy Vehicle (HOV) lanes. It amends a federal transportation code provision to change the deadline from September 30, 2025, to September 30, 2026. The change directly affects states operating HOV lanes that currently grant these exemptions. The bill makes a technical adjustment to the existing law without altering the exemption rules or adding new requirements.
This bill authorizes the posthumous presentation of a Congressional Gold Medal to Welles Remy Crowther, a volunteer firefighter and equities trader who died saving others during the September 11, 2001, attacks. The medal, designed by the Treasury Secretary, will be given to Crowther’s mother, Alison Crowther, following a formal presentation by congressional leaders. The bill also permits the U.S. Mint to sell bronze duplicates of the medal at cost to cover production expenses. It is a purely commemorative measure with no legislative or regulatory impact.
HR 5529, the Fair Housing for Disabled Veterans Act, changes how veteran disability payments are treated when determining eligibility for low-income housing programs. Specifically, it amends the tax code to exclude disability compensation or pension payments (under 38 U.S.C. chapters 11 or 15) from income calculations for low-income housing tax credits and residential rental project bonds. This means disabled veterans applying for these housing assistance programs will not have their disability benefits counted as income, potentially making them eligible for more housing options they otherwise might have been disqualified from. The bill directly affects disabled veterans seeking affordable housing through these federally supported programs.
HR 5526, the Biosimilar Red Tape Elimination Act, streamlines the U.S. Food and Drug Administration’s (FDA) process for approving biosimilar drugs that can be used interchangeably with brand-name biologic medications. It establishes a 60-day transition period after enactment to clarify when biosimilars are deemed "interchangeable" with reference drugs, preserving existing exclusivity periods for products licensed before the law’s passage. This affects pharmaceutical manufacturers developing biosimilars, the FDA (which must update its guidance within 18 months), and healthcare systems seeking lower-cost treatment options. The bill removes redundant language from existing laws and ensures the FDA’s approval standards for biosimilars remain unchanged, focusing on regulatory clarity rather than altering drug safety or efficacy requirements.
This bill requires health plans and insurers to create a clear, timely process for patients or doctors to request exceptions when step therapy protocols (which force patients to try cheaper drugs first) might harm them. It mandates approval for exceptions in six specific cases, such as when prior treatments failed, delaying care risks severe harm, or the required drug causes adverse reactions. Plans must respond within 72 hours (24 hours for emergencies) and cover the requested drug for at least one year if approved. Additionally, health plans must report annual data on exception requests, approvals, denials, and reasons to the government for transparency.
This bill prohibits U.S. courts from enforcing judgments based on Shari'a or any foreign law if they conflict with constitutional rights, particularly in family law cases like divorce, child custody, or inheritance. It requires courts to apply only U.S. law when foreign legal systems would violate fundamental rights such as due process, equal protection, or freedom from coercion. Contracts may still reference foreign law, but enforcement is blocked if it infringes constitutional protections. The law aims to ensure all court decisions comply with U.S. constitutional standards nationwide.
The MAP Roads Act establishes a federal pilot program to fund states in digitizing county road records and creating publicly accessible digital maps. It directly affects rural counties and state transportation departments by providing grants to convert paper maps into standardized digital formats, ensuring datasets distinguish public vs. private roads and work with mapping platforms. States must use funds for digitization, training, and building centralized repositories updated annually, with $20 million authorized yearly from 2026-2031. The program aims to improve rural commerce, safety, and navigation without altering road jurisdiction or ownership under existing law.
HR 5455, the Aviation Funding Stability Act of 2025, ensures continued operation of the Federal Aviation Administration (FAA) during government funding gaps. If Congress fails to pass regular appropriations or a continuing resolution before the new fiscal year begins, the bill allows the FAA to use existing funds from the Airport and Airway Trust Fund to maintain essential programs and airport infrastructure at the previous year’s funding level. This prevents shutdowns for FAA operations like air traffic control, airport grants, and safety programs for up to 30 days or until regular funding is enacted. The bill directly affects all FAA programs funded through the trust fund, including airport improvements and aviation safety initiatives, without creating new policies or altering funding levels.
The America’s CHILDREN Act of 2025 would create a pathway to permanent residency for young adults who entered the U.S. as children and were dependents of nonimmigrant workers (with specific work visas, excluding certain categories) for at least 8 years. To qualify, applicants must have graduated from a U.S. college or university, been lawfully present in the U.S. for 10 years total, and meet other eligibility criteria like not being inadmissible. The bill includes key protections: it prevents "aging out" by using the date a parent’s visa petition was filed to determine child status (instead of current age), allows reconsideration of past denials under the new rules, and retains priority dates for family-based immigration applications. This directly affects young adults who grew up under these visa statuses and completed higher education in the U.S.
S 2907, the Chloe Cole Act, prohibits health care professionals, hospitals, or clinics from performing "chemical or surgical mutilation" on minors under 18. This includes using puberty blockers, sex hormones, or surgeries intended to alter a child's body to align with a gender identity different from their sex assigned at birth. The law creates a private right of action, allowing victims or their guardians to sue providers in federal court for damages - including emotional distress and punitive damages - unless the treatment qualifies under specific exceptions (e.g., medically necessary care for disorders of sexual development, injuries, or detransition). It explicitly excludes counseling, referrals, or discussions of treatment options from liability, and sets a 25-year statute of limitations for lawsuits starting from the victim’s 18th birthday.
This bill (HR 5467, the PAAT Act) requires Medicare Part D plans to cover specific drugs treating autoimmune diseases, hemophilia, and Von Willebrand disease starting in 2027. It directly affects Medicare beneficiaries with these conditions by mandating plan coverage for relevant medications. Key provisions include requiring plans to include all covered drugs for these conditions and prohibiting prior authorization for such drugs more than once per year, unless the drug is short-term, a controlled substance, or has a risk management strategy. The law aims to reduce coverage barriers for these treatments without altering drug approval or pricing.
